CA2779532C - Synergistic antiviral composition and use thereof - Google Patents

Synergistic antiviral composition and use thereof Download PDF

Info

Publication number
CA2779532C
CA2779532C CA2779532A CA2779532A CA2779532C CA 2779532 C CA2779532 C CA 2779532C CA 2779532 A CA2779532 A CA 2779532A CA 2779532 A CA2779532 A CA 2779532A CA 2779532 C CA2779532 C CA 2779532C
Authority
CA
Canada
Prior art keywords
iota
carrageenan
kappa
neuraminidase inhibitor
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2779532A
Other languages
English (en)
French (fr)
Other versions
CA2779532A1 (en
Inventor
Andreas Grassauer
Eva Prieschl-Grassauer
Christiane Meier
Marielle Konig-Schuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinomed Biotech AG
Original Assignee
Marinomed Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2779532(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Marinomed Biotech AG filed Critical Marinomed Biotech AG
Publication of CA2779532A1 publication Critical patent/CA2779532A1/en
Application granted granted Critical
Publication of CA2779532C publication Critical patent/CA2779532C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2779532A 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof Active CA2779532C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28214809P 2009-12-22 2009-12-22
US61/282,148 2009-12-22
PCT/EP2010/007726 WO2011076367A2 (en) 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof

Publications (2)

Publication Number Publication Date
CA2779532A1 CA2779532A1 (en) 2011-06-30
CA2779532C true CA2779532C (en) 2018-05-22

Family

ID=44063696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779532A Active CA2779532C (en) 2009-12-22 2010-12-17 Synergistic antiviral composition and use thereof

Country Status (21)

Country Link
US (1) US10022449B2 (enExample)
EP (1) EP2515889B1 (enExample)
JP (1) JP5902628B2 (enExample)
KR (1) KR101862415B1 (enExample)
CN (1) CN102652017A (enExample)
AU (1) AU2010335594B2 (enExample)
BR (1) BR112012015202B1 (enExample)
CA (1) CA2779532C (enExample)
CL (1) CL2012001695A1 (enExample)
DK (1) DK2515889T3 (enExample)
EA (1) EA022840B1 (enExample)
ES (1) ES2531367T3 (enExample)
IL (1) IL219552A (enExample)
MX (1) MX2012007166A (enExample)
NZ (1) NZ599839A (enExample)
PL (1) PL2515889T3 (enExample)
PT (1) PT2515889E (enExample)
SG (1) SG181421A1 (enExample)
SI (1) SI2515889T1 (enExample)
WO (1) WO2011076367A2 (enExample)
ZA (1) ZA201202482B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126777A1 (en) * 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
RU2469020C1 (ru) * 2011-11-08 2012-12-10 Александр Васильевич Иващенко (3r,4r,5s)-5-амино-4-ациламино-3-(1-этил-пропокси)-циклогекс-1-ен-карбоновые кислоты, их эфиры и способ применения
RU2520836C1 (ru) * 2013-02-27 2014-06-27 Александр Васильевич Иващенко (3r,4r,5s)-4-амино-5-(2,2-дифторацетиламино)-3-(1-этилпропокси)-циклогекс-1-енкарбоновая кислота и ее эфиры, способ их получения и применения
PT2898888T (pt) * 2014-01-22 2019-07-16 Visufarma B V Composição que compreende iota-carragenina contra conjuntivite viral
US12594285B2 (en) 2016-02-25 2026-04-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) * 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
US11304989B2 (en) * 2017-10-06 2022-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Peptides for use in the treatment of viral infections
WO2019160261A1 (ko) * 2018-02-14 2019-08-22 (주)나노메디카 항바이러스 처리 방법, 항바이러스 필터, 및 이를 구비한 마스크
KR102316819B1 (ko) * 2018-04-20 2021-10-25 한미약품 주식회사 카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제
GB2579600B (en) 2018-12-05 2023-07-05 Byotrol Plc Anti-viral composition
MX2021016040A (es) * 2019-07-03 2022-03-11 Aillis Inc Composicion farmaceutica para el tratamiento de infecciones de virus de influenza.
WO2021184123A1 (en) * 2020-03-18 2021-09-23 Encyt Technologies, Inc. Compositions and methods for the treatment of coronavirus infection and respiratory compromise

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593314B1 (en) * 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
JP2001181188A (ja) * 1999-12-28 2001-07-03 Marine Biotechnol Inst Co Ltd インフルエンザウイルス感染阻害剤
SI2101792T1 (sl) 2006-12-05 2010-08-31 Marinomed Biotechnologie Gmbh Uporaba karagenana za zdravljenje rinovirusnih infekcij
EP1930015A1 (en) * 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
WO2008147468A2 (en) 2006-12-18 2008-12-04 Amcol International Compositions comprising virus-interacting layered phyllosilicates and a therapeutic agent, and methods of use
SI2178533T1 (sl) * 2007-08-24 2013-07-31 Marinomed Biotechnologie Gmbh Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan

Also Published As

Publication number Publication date
DK2515889T3 (en) 2015-03-02
AU2010335594B2 (en) 2015-05-21
IL219552A0 (en) 2012-06-28
NZ599839A (en) 2014-02-28
AU2010335594A1 (en) 2012-05-24
CL2012001695A1 (es) 2013-03-08
ZA201202482B (en) 2012-12-27
SI2515889T1 (sl) 2015-04-30
US20120302522A1 (en) 2012-11-29
WO2011076367A2 (en) 2011-06-30
PT2515889E (pt) 2015-03-20
KR20120107970A (ko) 2012-10-04
SG181421A1 (en) 2012-07-30
EA022840B1 (ru) 2016-03-31
CN102652017A (zh) 2012-08-29
WO2011076367A3 (en) 2011-09-01
EP2515889A2 (en) 2012-10-31
JP5902628B2 (ja) 2016-04-13
KR101862415B1 (ko) 2018-05-29
BR112012015202A2 (pt) 2016-04-05
EA201290373A1 (ru) 2012-11-30
MX2012007166A (es) 2012-07-23
CA2779532A1 (en) 2011-06-30
JP2013515022A (ja) 2013-05-02
EP2515889B1 (en) 2014-12-10
BR112012015202B1 (pt) 2020-12-08
IL219552A (en) 2016-11-30
US10022449B2 (en) 2018-07-17
PL2515889T3 (pl) 2015-05-29
ES2531367T3 (es) 2015-03-13

Similar Documents

Publication Publication Date Title
AU2010335594B2 (en) Synergistic antiviral composition and use thereof
FI2265257T4 (fi) Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi
US20220387455A1 (en) Treatment of moderate to severe influenza
Tu et al. Localized delivery of nanomedicine and antibodies for combating COVID-19
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JP5828007B2 (ja) 局所投与型の嚥下障害改善用医薬品
AU2021235223A1 (en) Composition for the treatment of lesions of the respiratory system
HK1174835A (en) Synergistic antiviral composition and use thereof
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
US20240415944A1 (en) Aqueous aprotinin-containing antiviral pharmaceutical composition
WO2025067689A1 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione for the treatment of infections with an rna virus
KR102088662B1 (ko) 연하장애 개선용 의약품
CN102641266A (zh) 一种治疗病毒性感冒的药物组合物
JP2021161105A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JP2004352712A (ja) インフルエンザの予防または治療剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241128

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241128

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260801